吸入糖皮质激素在慢阻肺治疗中是友还是敌?
该综述批判性评估了吸入糖皮质激素(ICS)治疗慢阻肺患者的疗效与安全性证据。文章提出ICS不应作为单药治疗,并明确了最可能获益的人群特征及肺炎风险增高的因素,强调需个体化权衡后决定是否在长效支气管扩张剂基础上加用ICS。
要点
- ICS不应作为慢阻肺的单药治疗。
- 多次或严重急性加重且血嗜酸性粒细胞>300 cells·µL-1者及有哮喘病史者最可能获益。
- 高龄、低BMI、脆弱、高ICS剂量及血嗜酸性粒细胞<100 cells·µL-1者肺炎风险更高。
核心结论
- ICS在慢阻肺患者中可能是有益的(friend)也可能是有害的(foe),需个体化评估后决定是否加用。
研究设计与样本
- 综述类文章,批判性回顾了支持与反对ICS治疗慢阻肺患者的证据。
主要发现
- ICS对部分患者有明确临床获益,但对另一些患者无效或与肺炎等不良事件相关。
- 多次或严重急性加重且血嗜酸性粒细胞>300 cells·µL-1者及有哮喘病史者最可能从ICS联合长效支气管扩张剂中获益。
- 高龄、低BMI、整体脆弱、接受较高ICS剂量及血嗜酸性粒细胞<100 cells·µL-1的慢阻肺患者使用ICS时肺炎风险更高。
关键数值与推荐
- ICS不应作为慢阻肺的单一、独立治疗。
- 在适当维持支气管扩张剂治疗下仍发生多次或严重急性加重,尤其血嗜酸性粒细胞>300 cells·µL-1者,及有哮喘病史和/或合并哮喘者,最可能受益于加用ICS。
- 使用ICS的慢阻肺患者中,高龄、低BMI、整体脆弱、接受较高ICS剂量及血嗜酸性粒细胞<100 cells·µL-1者肺炎风险更高。
临床怎么用
- 在给任何慢阻肺患者加用ICS前,需仔细考虑并平衡获益与肺炎风险因素。
- 不推荐ICS作为慢阻肺的单药治疗。
- 对多次或严重急性加重且血嗜酸性粒细胞>300 cells·µL-1或有哮喘病史者,可考虑在长效支气管扩张剂基础上加用ICS。
局限性
- 需要进一步研究以阐明某些问题并牢固确立这些推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can result in clear clinical benefits in some patients ("friend") but can be ineffective or even associated with undesired side effects, e.g. pneumonia, in others ("foe"). After critically reviewing the evidence for and against ICS treatment in patients with COPD, we propose that: 1) ICS should not be used as a single, stand-alone therapy in COPD; 2) patients most likely to benefit from the addition of ICS to long-acting bronchodilators include those with history of multiple or severe exacerbations despite appropriate maintenance bronchodilator use, particularly if blood eosinophils are >300 cells·µL-1, and those with a history of and/or concomitant asthma; and 3) the risk of pneumonia in COPD patients using ICS is higher in those with older age, lower body mass index (BMI), greater overall fragility, receiving higher ICS doses and those with blood eosinophils <100 cells·µL-1 All these factors must be carefully considered and balanced in any individual COPD patient before adding ICS to her/his maintenance bronchodilator treatment. Further research is needed to clarify some of these issues and firmly establish these recommendations.
引用
- Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J. 2018. PMID: 30190269. doi:10.1183/13993003.01219-2018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。